Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma

Abstract Chimeric Antigen Receptor (CAR) T cells directed to B cell maturation antigen (BCMA) mediate profound responses in patients with multiple myeloma, but most patients do not achieve long-term complete remissions. In addition, recent evidence suggests that high-affinity binding to BCMA can res...

Full description

Bibliographic Details
Main Authors:	Rebecca C. Larson, Michael C. Kann, Charlotte Graham, Christopher W. Mount, Ana P. Castano, Won-Ho Lee, Amanda A. Bouffard, Hana N. Takei, Antonio J. Almazan, Irene Scarfó, Trisha R. Berger, Andrea Schmidts, Matthew J. Frigault, Kathleen M. E. Gallagher, Marcela V. Maus
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-11-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-023-43416-7

Similar Items

767 Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies
by: Marcela Maus, et al.
Published: (2020-11-01)

CAR-Based Approaches to Cutaneous T-Cell Lymphoma
by: Irene Scarfò, et al.
Published: (2019-04-01)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01)

BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01)

Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
by: Xiangmin Wang, et al.
Published: (2021-12-01)

BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma
by: Debasmita Dutta, et al.
Published: (2023-12-01)

CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism
by: Johannes Nelke, et al.
Published: (2020-01-01)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
by: Quan Ren, et al.
Published: (2023-11-01)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01)

Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?
by: Shengli Xu, et al.
Published: (2020-04-01)

Transmembrane activator and CAML interactor (TACI) : another potential target for immunotherapy of multiple myeloma?
by: Xu, Shengli, et al.
Published: (2021)

BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis.
by: Vassiliki Pelekanou, et al.
Published: (2013-01-01)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
by: Benedetta Dalla Palma, et al.
Published: (2020-09-01)

BCMA in Multiple Myeloma—A Promising Key to Therapy
by: Martina Kleber, et al.
Published: (2021-09-01)

Jesteśmy wciąż tacy sami
by: Tadeusz Sobolewski
Published: (2008-03-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
by: Borja Puertas, et al.
Published: (2022-03-01)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
by: Abhinava K. Mishra, et al.
Published: (2023-11-01)

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells
by: Sandy W. Wong, et al.
Published: (2021-12-01)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
by: A. Visram, et al.
Published: (2021-06-01)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
by: Mehmet Kemal Samur, et al.
Published: (2021-02-01)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
by: Surbhi Sidana, et al.
Published: (2023-10-01)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
by: Yuan Xia, et al.
Published: (2023-11-01)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
by: Robert Berahovich, et al.
Published: (2018-09-01)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
by: Leah M. Alabanza, et al.
Published: (2022-02-01)

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
by: Shih-Feng Cho, et al.
Published: (2020-06-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
by: Lijie Xing, et al.
Published: (2023-04-01)

“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy
by: Nausheen Ahmed, et al.
Published: (2023-08-01)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: C. Li, et al.
Published: (2022-06-01)

271 Development and characterisation of humanised scFv CAR-T therapies targeting BCMA against multiple myeloma
by: Susana Inogés, et al.
Published: (2023-11-01)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
by: Endeshaw Chekol Abebe, et al.
Published: (2022-09-01)

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
by: David Gfeller, et al.
Published: (2022-11-01)

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion
by: Ting Wang, et al.
Published: (2022-05-01)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
by: Heng Mei, et al.
Published: (2021-10-01)

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
by: Ikhwan Rinaldi, et al.
Published: (2022-07-01)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
by: Lijun Wu, et al.
Published: (2022-05-01)

Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma
by: Thomas, Eloise, et al.
Published: (2022)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
by: Vita Golubovskaya, et al.
Published: (2021-10-01)

P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.
by: N. Asherie, et al.
Published: (2022-06-01)